Market closed

Apellis Pharmaceuticals/$APLS

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Ticker

$APLS
Trading on

Industry

Biotechnology

Employees

704

APLS Metrics

BasicAdvanced
$4.1B
Market cap
-
P/E ratio
-$2.03
EPS
0.87
Beta
-
Dividend rate
$4.1B
0.87
$73.80
$24.34
3.6M
4.36
3.595
195.536
198.4
-6.16%
-16.23%
-106.56%
5.703
17.06
17.06
-19.841
162.10%
-61.10%
40.79%
-32.04%

What the Analysts think about APLS

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Apellis Pharmaceuticals stock.

APLS Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

APLS Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $APLS

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Apellis Pharmaceuticals stock?

Apellis Pharmaceuticals (APLS) has a market cap of $4.1B as of December 21, 2024.

What is the P/E ratio for Apellis Pharmaceuticals stock?

The price to earnings (P/E) ratio for Apellis Pharmaceuticals (APLS) stock is 0 as of December 21, 2024.

Does Apellis Pharmaceuticals stock pay dividends?

No, Apellis Pharmaceuticals (APLS) stock does not pay dividends to its shareholders as of December 21, 2024.

When is the next Apellis Pharmaceuticals dividend payment date?

Apellis Pharmaceuticals (APLS) stock does not pay dividends to its shareholders.

What is the beta indicator for Apellis Pharmaceuticals?

Apellis Pharmaceuticals (APLS) has a beta rating of 0.87. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.